Ken Griffin Galapagos Nv Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$24.78 - $32.48 $101,598 - $133,168	4,100 Added 41.84%	13,900 $344,000
Q1 2024 May 15, 2024	BUY	$32.2 - $42.44 $103,040 - $135,808	3,200 Added 48.48%	9,800 $315,000
Q4 2023 Feb 14, 2024	SELL	$31.87 - $40.71 $76,488 - $97,704	-2,400 Reduced 26.67%	6,600 $268,000
Q3 2023 Nov 14, 2023	SELL	$34.17 - $42.98 $546,720 - $687,680	-16,000 Reduced 64.0%	9,000 $310,000
Q2 2023 Aug 14, 2023	SELL	$37.4 - $44.52 $396,440 - $471,912	-10,600 Reduced 29.78%	25,000 $1.02 Million
Q1 2023 May 15, 2023	SELL	$36.5 - $48.0 $759,200 - $998,400	-20,800 Reduced 36.88%	35,600 $1.38 Million
Q4 2022 Feb 14, 2023	BUY	$37.44 - $46.51 $1.44 Million - $1.79 Million	38,400 Added 213.33%	56,400 $2.5 Million
Q3 2022 Nov 14, 2022	BUY	$42.27 - $57.6 $101,448 - $138,240	2,400 Added 15.38%	18,000 $768,000

17.4M

10.4K

33.1K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $2B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.